
Sign up to save your podcasts
Or
Send us a text
New therapeutic options are now available for HR+ MBC. Dr. Virginia Kaklamani will discuss endocrine therapy resistance, liquid biopsy/blood test, mutations, and treatment sequencing of targeted therapy. You will learn about oral selective estrogen receptor degraders (SERDS), clinical trials, and more.
5
5858 ratings
Send us a text
New therapeutic options are now available for HR+ MBC. Dr. Virginia Kaklamani will discuss endocrine therapy resistance, liquid biopsy/blood test, mutations, and treatment sequencing of targeted therapy. You will learn about oral selective estrogen receptor degraders (SERDS), clinical trials, and more.
38,618 Listeners
90,409 Listeners
27,256 Listeners
78,125 Listeners
47 Listeners
43,880 Listeners
9,320 Listeners
12,625 Listeners
111,160 Listeners
55,977 Listeners
11,871 Listeners
5,678 Listeners
5,312 Listeners
15,510 Listeners
53 Listeners